Neoduplamox (Amoxicillin, Clavulanic Acid)

Amoxicillin, the active ingredient in Neoduplamox, is a penicillin class presented as an oral tablet for systemic use. It combines amoxicillin with clavulanic acid to broaden antibacterial coverage and is prescribed for a range of bacterial infections in adults and children when indicated by a healthcare professional. The formulation is designed for oral administration, providing convenient dosing and rapid absorption to achieve therapeutic levels in the bloodstream. It is commonly used in community and hospital settings to treat infections caused by beta‑lactamase‑producing organisms.

GNH USA supplies Neoduplamox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neoduplamox is used to treat bacterial infections affecting several organ systems, particularly the respiratory, ear, skin and urinary tracts. - Acute bacterial sinusitis: reduces symptoms and shortens disease duration. - Community‑acquired pneumonia: provides effective coverage against common respiratory pathogens. - Acute otitis media: resolves middle‑ear infection and alleviates pain. - Skin and soft‑tissue infections: treats cellulitis, abscesses and wound infections. - Urinary tract infections: eliminates susceptible uropathogens causing cystitis. - Exacerbations of chronic bronchitis: improves airflow and reduces bacterial load.

Amoxicillin/clavulanic acid is generally well tolerated, but adverse reactions may occur.

Common Side Effects: - Nausea: mild stomach upset often transient. - Diarrhea: loose stools, may be due to altered gut flora. - Rash: skin redness or itching. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Hepatic dysfunction: jaundice or elevated liver enzymes. - Neutropenia: low white‑blood‑cell count increasing infection risk. - Seizures: rare neurologic events, especially in renal impairment.

Before prescribing Neoduplamox, clinicians should evaluate patient history and monitor for potential risks. - Allergy assessment: confirm no known hypersensitivity to penicillins or β‑lactamase inhibitors. - Renal function: adjust dose in patients with impaired kidney function. - Hepatic disease: use with caution in patients with liver dysfunction. - Concomitant medications: review for drugs that may increase toxicity, such as methotrexate. - Pregnancy and lactation: weigh benefits against risks and consult obstetric guidance. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Neoduplamox can affect the activity of several medicines; awareness of key interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Allopurinol: increased risk of severe skin rash. - Methotrexate: heightened toxicity due to reduced renal clearance. - Warfarin: enhanced anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy, consider backup method. - Probenecid: decreased renal excretion of amoxicillin, raising plasma levels. - Diuretics: may increase risk of renal impairment and electrolyte disturbances.